Molecular diagnosis is performed at the gene level with nucleic acids as the object for detection, with high sensitivity and accuracy.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Bio-Techne said recently that its fiscal 2020 first quarter revenues rose 12 percent year over year, driven by growth in each of its business segments.

The National Institutes of Health has awarded researchers at the University of Virginia a $2.7 million grant to investigate how variation in a specific gene, called ID3, influences atherosclerosis.

Genialis recently announced a comarketing agreement with Thermo Fisher Scientific on data analysis for RNA sequencing.

Exact Sciences reported after the close of the market recently that its third quarter revenues rose 85 percent year over year, thanks to an 89 percent increase in testing volumes for its Cologuard colorectal cancer screening test.

LexaGene said recently that it has closed a previously announced financing round, grossing C$6.7 million (US$5.1 million).

Korean rare disease diagnostics firm 3billion said this week that it has raised $10 million in a Series B financing round.

Illumina and Qiagen recently announced a 15-year partnership to develop next-generation sequencing-based in vitro diagnostic kits, including companion diagnostics. The deal accompanied announcements that Qiagen CEO Peer Schatz would step dow

Genomic services provider Novogene has signed an agreement to develop a companion diagnostic for a cancer drug under development at Chipscreen Biosciences, the Chinese companies said today.

Thermo Fisher Scientific on Wednesday reported a 6 percent year-over-year increase in its third quarter revenues, driven by growth across most of its business segments.

Illumina reported after the close of the market on Thursday that its third quarter 2019 revenues grew 6 percent year over year.